Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Investment in die Zukunft: Absoluter Geheimtipp - diese Aktie beschleunigt deine Renditechancen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4Y0 | ISIN: KYG0028A1085 | Ticker-Symbol: 8ZD
Frankfurt
14.11.24
09:15 Uhr
0,515 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ABBISKO CAYMAN LTD Chart 1 Jahr
5-Tage-Chart
ABBISKO CAYMAN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3940,47407:00

Aktuelle News zur ABBISKO CAYMAN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:54Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type22
MiABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED RESULTS ON MODEL-INFORMED DOSE SELECTION FOR PIMICOTINIB AT ACOP 20241
DiAbbisko: Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial75- The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant...
► Artikel lesen
ABBISKO CAYMAN Aktie jetzt für 0€ handeln
DiABBISKO-B (02256): INSIDE INFORMATION - POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 MANEUVER STUDY OF PIMICOTINIB IN TGCT PATIENTS AND UPDATED RESULTS ...1
FrABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT PRELIMINARY PHASE 2 STUDY RESULTS OF PIMICOTINIB FOR THE TREATMENT OF CGVHD ...2
23.10.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL RESEARCH RESULTS OF ITS PRMT5*MTA AND ORAL KRASG12D PROGRAMS AT ...-
30.09.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL-
30.09.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE AND REPURCHASED SHARES CANCELLATION1
24.09.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABK3376 OBTAINED IND APPROVAL FROM NMPA-
19.09.ABBISKO-B (02256): 2024 INTERIM REPORT1
30.08.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
22.08.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
14.08.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
12.08.ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024-
26.07.ABBISKO-B (02256): DATE OF BOARD MEETING1
10.07.ABBISKO-B (02256): POSITIVE PROFIT ALERT-
04.07.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE1
03.07.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURN - CHANGES IN ISSUED SHARE CAPITAL1
28.06.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS-
28.06.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - 2024 ESMO-GI | ABBISKO THERAPEUTICS PRESENTS NEW PHASE II CLINICAL DATA OF IRPAGRATINIB IN COMBINATION WITH ...1
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1